Возраст домена | n/a |
Дата окончания | n/a |
PR | 4 |
ИКС | |
Страниц в Google | 37 |
Страниц в Яндексе | 4 |
Dmoz | Нет |
Яндекс Каталог | Нет |
Alexa Traffic Rank | 10360984 |
Alexa Country | Нет данных |
История изменения показателей | Авторизация |
Идет сбор информации... Обновить
Visterra - Visterra
n/a
n/a
UTF-8
70.62 КБ
2 500
39 375 симв.
33 474 симв.
Данные предоставлены сервисом semrush
Сайт | Общие фразы | PR | тИЦ | Alexa Rank | Alexa Country | |
---|---|---|---|---|---|---|
yelp.com | 11 | 7 |
0 | 201 | 39 | |
visterracu.org | 9 | 3 |
0 | 503640 | 100595 | |
immunize.org | 9 | n/a | 0 | 131094 | 34918 | |
cdc.gov | 9 | 9 |
0 | 1483 | 400 | |
vis.org | 7 | 5 |
0 | 11351182 | Нет данных | |
vissolis.us | 7 | 3 |
0 | 28822788 | Нет данных | |
visracing.com | 7 | 4 |
20 | 583968 | 201471 | |
va.gov | 7 | 8 |
0 | 4172 | 745 | |
uky.edu | 7 | 7 |
0 | 9557 | 2403 | |
caltech.edu | 7 | 8 |
0 | 7944 | 2918 | |
Еще 40 сайтов после авторизации |
Данные предоставлены сервисом semrush
Счетчик | Посетители за 24 часа | Просмотры | Просмотров на посетителя |
---|---|---|---|
Google Analytics | Нет доступа | Нет доступа | n/a |
Данные linkpad ( 15 Сентября 2014 ) | |
Количество ссылок на сайт | 107 |
Количество доменов, которые ссылаются на сайт | 14 |
Количество найденных анкоров | 6 |
Исходящие (внешние) ссылки домена | 9 |
Количество доменов, на которые ссылается сайт | 9 |
Количество исходящих анкоров | 3 |
Внешние ссылки главной страницы ( 38 ) | |
otsuka-us.com/ | <img> |
ncbi.nlm.nih.gov/pubmed/29984452 | Antibody-Bactericidal Macrocyclic Peptide Conjugates to Target Gram Negative Bacteria. Chembiochem. |
tandfonline.com/doi/full/10.1080/19420862.2018.1490119 | Extending human IgG half-life using structure-guided design. |
ncbi.nlm.nih.gov/pubmed/29425203 | Neutralization of antibody-enhanced dengue infection by VIS513, a pan serotype reactive monoclonal antibody targeting domain III... |
ncbi.nlm.nih.gov/pubmed/28529000 | Preclinical evaluation of VIS513, a therapeutic antibody against dengue virus, in non-human primates. |
ncbi.nlm.nih.gov/pubmed/27751627 | A Structural and Mathematical Modeling Analysis of the Likelihood of Antibody-Dependent Enhancement in Influenza. |
ncbi.nlm.nih.gov/pubmed/26787699 | The Hemagglutinin Stem-Binding Monoclonal Antibody VIS410 Controls Influenza Virus-Induced Acute Respiratory Distress Syndrome. |
ncbi.nlm.nih.gov/pmc/articles/PMC4816807/ | Safety and Upper Respiratory Pharmacokinetics of the Hemagglutinin Stalk-Binding Antibody VIS410 Support Treatment and Prophylax... |
ncbi.nlm.nih.gov/pubmed/26217334 | Antibody-Based Strategies to Prevent and Treat Influenza. |
pnas.org/content/early/2015/08/12/1502374112.short | A broadly neutralizing human monoclonal antibody is effective against H7N9. |
sciencedirect.com/science/article/pii/S0092867415008272 | Structure-Guided Design of an Anti-dengue Antibody Directed to a Non-immunodominant Epitope. |
ncbi.nlm.nih.gov/pubmed/23746830 | Glycan receptor binding of the influenza A virus H7N9 hemagglutinin. |
ncbi.nlm.nih.gov/pubmed/23746829 | Structural determinants for naturally evolving H5N1 hemagglutinin to switch its receptor specificity. |
ncbi.nlm.nih.gov/pubmed/23707399 | Recognition of heparan sulfate by clinical strains of dengue virus serotype 1 using recombinant subviral particles. |
ncbi.nlm.nih.gov/pubmed/23626667 | Antigenically intact hemagglutinin in circulating avian and swine influenza viruses and potential for H3N2 pandemic. |
ncbi.nlm.nih.gov/pubmed/23587408 | Modular glycosphere assays for high-throughput functional characterization of influenza viruses.BMC Biotechnol. |
ncbi.nlm.nih.gov/pubmed/23569282 | Redesign of a cross-reactive antibody to dengue virus with broad-spectrum activity and increased in vivo potency. |
ncbi.nlm.nih.gov/pubmed/23437033 | Quantitative description of glycan-receptor binding of influenza A virus H7 hemagglutinin. |
ncbi.nlm.nih.gov/pubmed/22355715 | Glycosylation at Asn91 of H1N1 haemagglutinin affects binding to glycan receptors. |
ncbi.nlm.nih.gov/pubmed/21410647 | Glycomics-based analysis of chicken red blood cells provides insight into the selectivity of the viral agglutination assay. |
ncbi.nlm.nih.gov/pubmed/21407805 | A single base-pair change in 2009 H1N1 hemagglutinin increases human receptor affinity and leads to efficient airborne viral tra... |
ncbi.nlm.nih.gov/pubmed/21060797 | Determinants of glycan receptor specificity of H2N2 influenza A virus hemagglutinin. |
ncbi.nlm.nih.gov/pubmed/20734133 | Glycans as receptors for influenza pathogenesis. |
ncbi.nlm.nih.gov/pubmed/20574518 | Receptor specificity and transmission of H2N2 subtype viruses isolated from the pandemic of 1957. |
ncbi.nlm.nih.gov/pubmed/19900932 | Hemagglutinin receptor binding avidity drives influenza A virus antigenic drift. |
ncbi.nlm.nih.gov/pubmed/19716471 | Context-specific target definition in influenza a virus hemagglutinin-glycan receptor interactions. |
ncbi.nlm.nih.gov/pubmed/19574347 | Transmission and pathogenesis of swine-origin 2009 A(H1N1) influenza viruses in ferrets and mice. |
ncbi.nlm.nih.gov/pubmed/19513050 | Extrapolating from sequence–the 2009 H1N1 ‘swine’ influenza virus. |
ncbi.nlm.nih.gov/pubmed/18287068 | Quantitative biochemical rationale for differences in transmissibility of 1918 pandemic influenza A viruses. |
ncbi.nlm.nih.gov/pubmed/18176555 | Glycan topology determines human adaptation of avian H5N1 virus hemagglutinin. |
rdmag.com/article/2015/09/better-flu-antibodies | Better Flu Antibodies |
vaccinenewsdaily.com/stories/510627400-new-visterra-antibody... | New Visterra Antibody Broadly Neutralizes Dengue Virus in Studies |
fiercebiotech.com/biotech/merck-led-syndicate-bets-30m-on-vi... | Merck-Led Syndicate Bets $30M on Visterra's Infectious-Disease Pipeline |
bizjournals.com/boston/blog/bioflash/2014/10/visterra-gets-3... | Visterra Gets $30M for Flu Drug as Sarepta, Alere Also Advance Treatments |
xconomy.com/boston/2013/12/02/visterra-adds-8m-ex-amag-execs... | Visterra Adds $8M, Ex-Amag Execs, To Begin Clinical Push for Flu Antibody |
fiercebiotech.com/special-reports/visterra-fiercebiotechs-20... | Visterra: 2013 Fierce 15 |
fiercebiotech.com/story/visterras-engineered-antibody-passes... | Visterra's Engineered Antibody Passes Preclinical Test as Universal Flu Treatment |
xconomy.com/boston/2012/11/09/gates-foundation-invests-in-fl... | Gates Foundation Invests in Flu Drug Developer Visterra |
Внутренние ссылки главной страницы ( 55 ) | |
#home | <img> |
visterrainc.com/wp-content/uploads/2018/11/2018-1115-VISTERR... | Visterra Presents Data Demonstrating Safety, Tolerability and Positive Clinical Activity Trends of VIS410 in Non-hospitalized Pa... |
visterrainc.com/wp-content/uploads/2018/11/2018-1108-VISTERR... | Visterra Initiates Phase 1 Clinical Study of VIS649 |
visterrainc.com/pdfs/publications/2015%2005%20Visterra%20Cur... | Amino acid interaction networks provide a new lens for therapeutic antibody discovery and anti-viral drug optimization. |
visterrainc.com/pdfs/publications/ICAAC%20Presentation%20201... | VIS410, a broadly HA-targeting human antibody, neutralizes H5 and H7 isolates with pandemic potential |
visterrainc.com/pdfs/publications/IDSAposter.pdf | Identification and Characterization of Broadly Neutralizing Antibodies Influenza |
visterrainc.com/pdfs/publications/ICAAC-VIS410-Presentation-... | Design of a Broadly Neutralizing Antibody Targeting Influenza A |
visterrainc.com/wp-content/uploads/2018/11/2018-0905-Visterr... | Otsuka Pharmaceutical Completes Acquisition of Visterra |
visterrainc.com/wp-content/uploads/2018/11/2018-0711-Otsuka.... | Otsuka Pharmaceutical to Acquire Visterra |
visterrainc.com/wp-content/uploads/2018/11/2018-0307-Visterr... | Visterra to Present New Preclinical Data on VIS410 for Influenza A at the International Meeting on Respiratory Pathogens |
visterrainc.com/wp-content/uploads/2018/11/2018-0212-Visterr... | Visterra Announces Publication in the Journal PLOS Neglected Tropical Diseases Demonstrating that Novel Antibody, VIS513, Broadl... |
visterrainc.com/wp-content/uploads/2018/11/2017-1101-Visterr... | FDA Grants Fast Track Designation to Visterra’s VIS410 for Treatment of Hospitalized Patients with Influenza A |
visterrainc.com/wp-content/uploads/2018/11/2017-1031-Visterr... | Visterra to Present New Preclinical Results on VIS649, its Antibody for the Treatment of IgA Nephropathy, at the American Societ... |
visterrainc.com/wp-content/uploads/2018/11/2017-1018-Visterr... | Visterra Announces Research Collaboration, Exclusive License, and Option Agreement for Infectious Diseases with Vir Biotechnolog... |
visterrainc.com/wp-content/uploads/2018/11/2017-1005-Visterr... | Visterra Closes $46.7 Million Series C Financing to Advance Pipeline of Precision Antibody-Based Biological Medicines |
visterrainc.com/wp-content/uploads/2018/11/2017-0331-Visterr... | Visterra to Present at 16th Annual Needham Healthcare Conference |
visterrainc.com/wp-content/uploads/2018/11/2017-0330-Visterr... | Visterra Awarded CARB-X Contract to Advance Development of VIS705 |
visterrainc.com/wp-content/uploads/2018/11/2017-0111-VIS410-... | Visterra Doses First Patient in Phase 2a Trial for VIS410, its Monoclonal Antibody in Development for the Treatment of Hospitali... |
visterrainc.com/wp-content/uploads/2018/11/2016-0824-Visterr... | Visterra to Present New Clinical Results of VIS410 at the Options IX for the Control of Influenza Conference |
visterrainc.com/wp-content/uploads/2018/11/2016-0421-Visterr... | Visterra Appoints Two Industry Leaders to its Board of Directors |
visterrainc.com/wp-content/uploads/2018/11/2016-0226-Visterr... | Visterra Announces Publication of Clinical Data on VIS410 in the Journal EBioMedicine |
visterrainc.com/wp-content/uploads/2018/11/2015-1005-Visterr... | Visterra’s Monoclonal Antibody in Development for the Treatment of Influenza A, VIS410, Demonstrated Significant Antiviral Activ... |
visterrainc.com/wp-content/uploads/2018/11/2015-1005-Visterr... | Visterra Awarded Contract Valued at up to $204.5 Million to Advance the Development of VIS410, its Novel Monoclonal Antibody for... |
visterrainc.com/wp-content/uploads/2018/11/2015-0909-Visterr... | Visterra, Inc. and Serum Institute of India Ltd. Announce Collaboration to Advance VIS513, a Monoclonal Antibody in Development ... |
visterrainc.com/wp-content/uploads/2018/11/2015-0902-Visterr... | Visterra Announces Appointment of John Weidenbruch as General Counsel |
visterrainc.com/wp-content/uploads/2018/11/2015-0818-Visterr... | Visterra Announces Publication of Data Demonstrating the Effectiveness of VIS410 Against Seasonal and Potential Pandemic Influen... |
visterrainc.com/wp-content/uploads/2018/11/2015-0716-Visterr... | Visterra Announces Publication in the Journal, Cell, Demonstrating Novel Antibody, VIS513, Broadly Neutralizes All Four Serotype... |
visterrainc.com/wp-content/uploads/2018/11/2015-0602-Visterr... | Visterra Announces Presentation of Data at International Influenza Meeting on the Efficacy of VIS410 for Treatment of a Deadly S... |
visterrainc.com/wp-content/uploads/2018/11/2015-0521-Visterr... | Visterra Partners with A*STAR to Develop VIS513, a Monoclonal Antibody for Dengue |
visterrainc.com/wp-content/uploads/2018/11/2014-1031-Visterr... | Visterra Announces Additions to its Management Team and Board of Directors |
visterrainc.com/wp-content/uploads/2018/11/2014-1002-Visterr... | Visterra Closes $30 Million Series B Financing to Advance Pipeline of Multiple Products for Infectious Diseases |
visterrainc.com/wp-content/uploads/2018/11/2014-0903-Visterr... | Visterra to Present Data at ICAAC on VIS513, its Humanized Monoclonal Antibody That Targets a Conserved Site on the Dengue Virus... |
visterrainc.com/wp-content/uploads/2018/11/2014-0113-Visterr... | Visterra to Present at the 32nd Annual J.P. Morgan Healthcare Conference |
visterrainc.com/wp-content/uploads/2018/11/2013-1202-Visterr... | Visterra Acquires Exclusive Patent License for Monoclonal Antibodies against Dengue Virus from MIT |
visterrainc.com/wp-content/uploads/2018/11/2013-1202-Visterr... | Visterra Closes $8.1 Million Financing and Expands Executive Team to Accelerate Company Growth |
visterrainc.com/wp-content/uploads/2018/11/2013-0924-Visterr... | Visterra Named One of the "Fierce 15" Leading Biotech Companies of 2013 |
visterrainc.com/wp-content/uploads/2018/11/2013-0912-Visterr... | Visterra Announces an Oral Presentation of VIS410 Data that Showed Neutralization of H5 and H7 Influenza Strains with Pandemic P... |
visterrainc.com/wp-content/uploads/2018/11/2013-0909-Visterr... | Visterra Presents Prophylactic and Therapeutic Efficacy Data of VIS410 Against Multiple Influenza Strains with Pandemic Potentia... |
visterrainc.com/wp-content/uploads/2018/11/2013-0715-Visterr... | Visterra Appoints Brian Pereira, M.D., as President and Chief Executive Officer |
visterrainc.com/wp-content/uploads/2018/11/2012-1109-Visterr... | Visterra Secures Financing From Gates Foundation and Omega to Close $26M Series A Financing |
visterrainc.com/wp-content/uploads/2018/11/2012-1029-VIS410D... | Visterra Presents Prophylactic and Therapeutic Efficacy Data of VIS410 Against the H5N1 (Avian Flu) Influenza Strain in Hanoi, V... |
visterrainc.com/wp-content/uploads/2018/11/2012-1020-VIS410I... | Visterra Presents Data on Broadly Neutralizing Influenza Antibodies at the Infectious Diseases Society of America (IDSA) Meeting |
visterrainc.com/wp-content/uploads/2018/11/2012-0911-Visterr... | Visterra Signs Antibody Discovery Collaboration Deal With Pfizer |
visterrainc.com/wp-content/uploads/2018/11/2012-0910-Visterr... | Visterra Presents Preclinical Results that Shows 100% Prevention and Treatment of Influenza with VIS410, a Novel Engineered Huma... |
/wp-content/uploads/2018/07/2017-1006-Visterra-BioWorldToday... | Making Music with MIT Tech | Flu Fighters: $46.7M Rocks Visterra, Pieces of APRIL Key in Nephropathy Bid |
/wp-content/uploads/2018/07/2012-1008-Visterra-BioCentury.pd... | New Vista Over Epitopes |
/wp-content/uploads/2018/07/2012-0912-Visterra-BioWorldToday... | Visterra Makes Debut at ICAAC With Flu Antibody, Partnership |
visterrainc.com/wp-content/uploads/2019/12/Associate-Scienti... | Associate Scientist, Research |
visterrainc.com/wp-content/uploads/2019/12/Research-Associat... | Research Associate |
visterrainc.com/wp-content/uploads/2019/11/Scientist-Cell-Cu... | Scientist, Cell Culture Development |
visterrainc.com/wp-content/uploads/2019/10/Laboratory-Techni... | Laboratory Technician |
visterrainc.com/wp-content/uploads/2019/10/Associate-Scienti... | Associate Scientist, Research |
visterrainc.com/wp-content/uploads/2019/10/Director-of-Clini... | Director of Clinical Translational Development |
visterrainc.com/wp-content/uploads/2019/09/Associate-Directo... | Associate Director or Director of Quality Assurance |
visterrainc.com/wp-content/uploads/2019/10/Senior-Director-I... | Senior Director, Intellectual Property |
Domain Name: VISTERRAINC.COM
Registrar URL: http://www.godaddy.com
Registrant Name: Anne Baia
Registrant Organization: X-BODY, Inc.
Name Server: NS17.DOMAINCONTROL.COM
Name Server: NS18.DOMAINCONTROL.COM
For complete domain details go to:
http://who.godaddy.com/whoischeck.aspx?domain=VISTERRAINC.COM
User-agent: *
Disallow: /wp-admin/
Allow: /wp-admin/admin-ajax.php
США - Пасадина - 131.215.239.141
California Institute of Technology
California Institute of Technology
HTTP/1.1 200 OK
Date: Tue, 24 Dec 2019 02:15:21 GMT
Server: Apache/2.4.39
X-Powered-By: PHP/7.2.12
X-Pingback: http://www.visterrainc.com/xmlrpc.php
Link: ; rel="https://api.w.org/", ; rel=shortlink
Vary: Accept-Encoding,User-Agent
Transfer-Encoding: chunked
Content-Type: text/html; charset=UTF-8
Кнопка для анализа сайта в один клик, для установки перетащите ссылку на "Панель закладок"